WO2000043395A1 - Substituted porphyrins - Google Patents

Substituted porphyrins Download PDF

Info

Publication number
WO2000043395A1
WO2000043395A1 PCT/US2000/002062 US0002062W WO0043395A1 WO 2000043395 A1 WO2000043395 A1 WO 2000043395A1 US 0002062 W US0002062 W US 0002062W WO 0043395 A1 WO0043395 A1 WO 0043395A1
Authority
WO
WIPO (PCT)
Prior art keywords
same
compound
manganese
mmol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/002062
Other languages
English (en)
French (fr)
Other versions
WO2000043395A8 (en
Inventor
James D. Crapo
Brian J. Day
Michael P. Trova
Polivini Jolicia F. Gauuan
Douglas B. Kitchen
Irwin Fridovich
Ines Batinic-Haberle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Jewish Health
Aeolus Pharmaceuticals Inc
Duke University
Original Assignee
Aeolus Pharmaceuticals Inc
National Jewish Medical and Research Center
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL14450300A priority Critical patent/IL144503A0/xx
Priority to NZ513164A priority patent/NZ513164A/xx
Priority to HK02109292.4A priority patent/HK1047744B/xx
Priority to MXPA01007451A priority patent/MXPA01007451A/es
Priority to AU27407/00A priority patent/AU779283B2/en
Priority to BRPI0007720-8B1A priority patent/BR0007720B1/pt
Priority to EP00905776A priority patent/EP1155019B1/en
Priority to CA002359116A priority patent/CA2359116C/en
Priority to JP2000594811A priority patent/JP4501128B2/ja
Application filed by Aeolus Pharmaceuticals Inc, National Jewish Medical and Research Center, Duke University filed Critical Aeolus Pharmaceuticals Inc
Priority to DE60024588T priority patent/DE60024588T2/de
Priority to AT00905776T priority patent/ATE312103T1/de
Publication of WO2000043395A1 publication Critical patent/WO2000043395A1/en
Publication of WO2000043395A8 publication Critical patent/WO2000043395A8/en
Priority to IL144503A priority patent/IL144503A/en
Anticipated expiration legal-status Critical
Priority to IL183953A priority patent/IL183953A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B47/00—Porphines; Azaporphines

Definitions

  • the compounds of the invention can also be used in methods designed to regulate NO- levels by targeting the above-described porphines to strategic locations.
  • NO- is an intercellular signal and, as such, NO- must traverse the extracellular matrix to exert its effects.
  • NO- is highly sensitive to inactivation mediated by O : " present in the extracellular spaces.
  • the methine (meso) substituted porphyrins of the invention can increase bioavalability of NO' by preventing its degradation by O- ' .
  • the invention further relates to methods of treating memory disorders. It is believed that nitric oxide is a neurotransmitter involved in long-term memory potentiation. Using an EC-SOD knocked-out mouse model (Carlsson et al. Proc. Natl. Acad. Sci. USA 92:6264 (1995)), it can be shown that learning impairment correlates with reduced superoxide scavenging in extracellular spaces of the brain. Reduced scavenging results in higher extracellular O 2 ' levels. O : ' is believed to react with nitric oxide thereby preventing or inhibiting nitric oxide-mediated neurotransmission and thus long-term memory potentiation.
  • the mimetics of the invention particularly, metal bound forms, can be used to treat dementias and memory/learning disorders. 00/43395
  • the animal received 0.25 mg/kg/24 hr given i.v. in a continuous infusion over the entire 10 day study period (see Fig. 2). This animal showed marked improvement of the oxygenation index. There was no evidence of clinical decompensation of the lungs at days 9 and 10. This suggests that Aeol-V can be used to treat oxidant stress in the premature newborn.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2000/002062 1999-01-25 2000-01-25 Substituted porphyrins Ceased WO2000043395A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2000594811A JP4501128B2 (ja) 1999-01-25 2000-01-25 置換ポルフィリン
HK02109292.4A HK1047744B (en) 1999-01-25 2000-01-25 Substituted porphyrins
MXPA01007451A MXPA01007451A (es) 1999-01-25 2000-01-25 Porfirinas sustituidas.
AU27407/00A AU779283B2 (en) 1999-01-25 2000-01-25 Substituted porphyrins
BRPI0007720-8B1A BR0007720B1 (pt) 1999-01-25 2000-01-25 Porfirinas substituídas e método de proteção de células contra toxicidade induzida por oxidante
EP00905776A EP1155019B1 (en) 1999-01-25 2000-01-25 Substituted porphyrins and their therapeutic use
CA002359116A CA2359116C (en) 1999-01-25 2000-01-25 Substituted porphyrins
IL14450300A IL144503A0 (en) 1999-01-25 2000-01-25 Substituted porphyrins
DE60024588T DE60024588T2 (de) 1999-01-25 2000-01-25 Substituierte porphyrine und deren therapeutische verwendungen
NZ513164A NZ513164A (en) 1999-01-25 2000-01-25 Substituted porphyrins
AT00905776T ATE312103T1 (de) 1999-01-25 2000-01-25 Substituierte porphyrine und deren therapeutische verwendungen
IL144503A IL144503A (en) 1999-01-25 2001-07-23 Dual-tetra-porphyrins - metabolized, to treat and prevent oxidation-induced toxicity, and some such new porphyrins
IL183953A IL183953A (en) 1999-01-25 2007-06-14 Method of reducing oxidant induced damage of a food product, a pharmaceutical or stored blood and novel compounds therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11701099P 1999-01-25 1999-01-25
US60/117,010 1999-01-25

Publications (2)

Publication Number Publication Date
WO2000043395A1 true WO2000043395A1 (en) 2000-07-27
WO2000043395A8 WO2000043395A8 (en) 2000-08-31

Family

ID=22370524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/002062 Ceased WO2000043395A1 (en) 1999-01-25 2000-01-25 Substituted porphyrins

Country Status (17)

Country Link
US (7) US6544975B1 (enExample)
EP (3) EP1616869B1 (enExample)
JP (1) JP4501128B2 (enExample)
KR (1) KR100753184B1 (enExample)
CN (1) CN1156478C (enExample)
AT (2) ATE552260T1 (enExample)
AU (1) AU779283B2 (enExample)
BR (1) BR0007720B1 (enExample)
CA (1) CA2359116C (enExample)
DE (1) DE60024588T2 (enExample)
DK (2) DK1616869T3 (enExample)
ES (2) ES2385486T3 (enExample)
IL (3) IL144503A0 (enExample)
MX (1) MXPA01007451A (enExample)
NZ (1) NZ513164A (enExample)
WO (1) WO2000043395A1 (enExample)
ZA (1) ZA200106107B (enExample)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2806911A1 (fr) * 2000-03-28 2001-10-05 Univ Rene Descartes Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
US6479477B1 (en) 1998-04-24 2002-11-12 Duke University Substituted porphyrins
US6544975B1 (en) 1999-01-25 2003-04-08 National Jewish Medical And Research Center Substituted porphyrins
US6583132B1 (en) 1993-10-15 2003-06-24 Duke University Oxidant scavengers
WO2002060383A3 (en) * 2001-01-19 2003-12-11 Nat Jewish Med & Res Center Cancer therapy
EP1442747A1 (en) * 1993-10-15 2004-08-04 Duke University Superoxide dismutase and mimetics thereof
AU2002253619B2 (en) * 2001-04-27 2007-05-17 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same active ingredients
US7432369B2 (en) 2004-03-29 2008-10-07 Inotek Pharmaceuticals Corporation Pyridyl-substituted porphyrin compounds and methods of use thereof
WO2008070579A3 (en) * 2006-12-01 2009-03-19 Univ Loma Linda Med Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration
EP1439842A4 (en) * 2001-06-01 2009-09-02 Nat Jewish Med & Res Center OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
KR20110017398A (ko) * 2008-05-23 2011-02-21 내셔날 쥬이쉬 헬스 알킬화 종으로의 노출과 관련된 상해를 치료하는 방법
EP2435387A4 (en) * 2009-05-26 2013-03-20 Univ Duke PROCESS FOR PROVIDING NERVE PROTECTION THROUGH THE USE OF PORPHYRINES
US20130225545A1 (en) * 2010-10-06 2013-08-29 Aeolus Sciences, Inc. Porphyrin treatment of neurodegenerative diseases
WO2015034778A1 (en) * 2013-09-03 2015-03-12 Biomimetix J.V., Llc Methods of treating erectile dysfunction
WO2016077857A1 (de) * 2014-11-20 2016-05-26 Wenatex Forschung - Entwicklung - Produktion Gmbh Antimikrobielles mittel zum biociden ausrüsten von polymeren
US10064871B2 (en) 2014-01-22 2018-09-04 Biomimetix Jv, Llc Methods of treating skin disorders
US10080759B2 (en) 2014-01-22 2018-09-25 Duke University Methods of treating pruritus
WO2020250207A1 (en) * 2019-06-14 2020-12-17 Universidade De Coimbra Small cationic ortho-5,15-di-heteroaryl-porphyrins derivatives and their applications in photoinactivation of microorganisms

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2198767T3 (es) 1997-11-03 2004-02-01 Duke University Porfirinas sustituidas.
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20030086916A1 (en) * 2001-10-12 2003-05-08 Goligorsky Michael S. Use of peroxynitrite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence
EP1513537A4 (en) * 2002-06-07 2006-09-06 Univ Duke Substituted porphyrins
US20040127479A1 (en) * 2002-08-27 2004-07-01 Merck Patent Gmbh Peroxynitrite rearrangement catalysts
CA2505608A1 (en) * 2002-12-06 2004-06-24 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
EP1452175A1 (en) * 2003-02-28 2004-09-01 Medesis Pharma S.A. Manganese based organometallic complexes, pharmaceutical compositions and dietetic products
US20080161255A1 (en) * 2003-05-29 2008-07-03 Michael Brownlee Use of Parp Inhibitors for Prevention and Treatment of Diabetic and Insulin Resistance Complications
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
WO2005077269A1 (en) 2004-02-09 2005-08-25 Duke University Substituted porphyrins
US8165651B2 (en) * 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
WO2006037050A2 (en) * 2004-09-24 2006-04-06 Metaphore Pharmaceuticals, Inc. Methods for treating congestive heart failure
GB0424294D0 (en) * 2004-11-03 2004-12-01 Elam T Ltd Buffer layer
US7582751B2 (en) * 2005-07-29 2009-09-01 North Carolina State University Methods and intermediates for the synthesis of porphyrins
US7501508B2 (en) * 2005-07-29 2009-03-10 North Caroline State University Methods and intermediates for the synthesis of porphyrins
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US20080289053A1 (en) * 2007-05-15 2008-11-20 The Regents Of The University Of California Methods and systems for identifying modulators of longevity
WO2009004339A2 (en) * 2007-07-03 2009-01-08 Imperial Innovations Limited Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection
EP2192899B1 (en) * 2007-08-28 2014-10-01 Technion Research and Development Foundation, Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US20120289492A1 (en) * 2009-09-02 2012-11-15 The Regents Of The University Of Colorado, A Body Corporate Methods of treating mitochondrial disorders using metalloporphyrins
WO2012105483A1 (ja) * 2011-01-31 2012-08-09 国立大学法人宇都宮大学 ポルフィリン型骨格を有する化合物の金属錯体の製造方法
WO2013130150A2 (en) 2011-12-02 2013-09-06 The Regents Of The University Of Colorado, A Body Corporate Metalloporphyrin neurological treatments
CN102775415B (zh) * 2012-07-10 2014-10-22 西北大学 一种卟啉的合成方法
WO2014028823A1 (en) * 2012-08-16 2014-02-20 Leading Energy Designs, Ltd. Led bracket apparatus for high-output led lighting systems
EP3488871B1 (en) 2013-03-14 2020-09-02 Profusa, Inc. Oxygen sensors
EP3071574A4 (en) * 2013-11-22 2017-05-10 Aeolus Sciences, Inc. Synthesis and formulations of porphyrin compounds
AU2014374361B9 (en) 2013-12-31 2019-07-04 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
WO2017031173A1 (en) 2015-08-18 2017-02-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Viologen-functionalized porphyrins for reducing biofouling on surfaces
WO2018118891A1 (en) * 2016-12-20 2018-06-28 Duke University Methods of making substituted porphyrin pharmaceutical compounds and compositions
EP3558118A4 (en) 2016-12-21 2021-02-24 Profusa, Inc. POLYMERIZABLE NEAR-INFRARED COLORS
WO2020006248A1 (en) 2018-06-27 2020-01-02 Soya Gamsey Near-ir glucose sensors
CN110028514B (zh) * 2019-05-30 2021-07-02 湖南科技大学 5,10,15,20-四芳基-2,3-咪唑稠合-21-碳叶绿素化合物及制备方法
US12201649B2 (en) 2021-11-12 2025-01-21 Villanova University Pharmaceutical composition comprising oxidizable biphenol and manganese porphyrin, and method of using the same
CN116284017B (zh) * 2023-03-27 2024-03-22 中国科学院青岛生物能源与过程研究所 一种利用仿酶高效催化氧化制备酰胺化合物的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885114A (en) * 1987-04-22 1989-12-05 Barnes Engineering Co. Metallized tetra((meso)-5-methyl-2-thiophene)porphines, platinum (5-bromo octaethylporphine) and optical filters containing same
US5236914A (en) * 1988-06-02 1993-08-17 Centre National De La Recherche Scientifique (Cnrs) Derivatives of metalloporphyrins and application thereof for therapeutic purposes and in preparing hybrid molecules

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US437221A (en) * 1890-09-30 Circular-saw-smithing machine
US2951799A (en) 1957-11-13 1960-09-06 Monsanto Chemicals Photoxidation processes using heterocyclic photosensitizers
JPS5641611B2 (enExample) * 1973-04-19 1981-09-29
DE3464252D1 (en) 1983-06-03 1987-07-23 Hoffmann La Roche Labelled molecules for fluorescence immunoassays and processes and intermediates for their preparation
US4829984A (en) * 1983-12-15 1989-05-16 Gordon Robert T Method for the improvement of transplantation techniques and for the preservation of tissue
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5087438A (en) * 1984-07-03 1992-02-11 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
GB8429845D0 (en) 1984-11-26 1985-01-03 Efamol Ltd Porphyrins & cancer treatment
US4758422A (en) 1985-01-04 1988-07-19 Salutar Inc. Ferrioxamine paramagnetic contrast agents for MR imaging
US4657902A (en) 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
AU587472B2 (en) 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
DK402785D0 (da) 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
US5248603A (en) 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4866054A (en) * 1986-05-13 1989-09-12 Chai-Tech Corporation Antioxidant metallo-organic treatment of inflammation
US4746735A (en) 1986-11-21 1988-05-24 The Dow Chemical Company Regiospecific aryl nitration of meso-substituted tetraarylporphyrins
US5162231A (en) 1989-10-25 1992-11-10 Cole Dean A Method of using 5,10,15,20-tetrakis(carboxyphenyl)porphine for detecting cancers of the lung
ATE132902T1 (de) 1987-03-14 1996-01-15 Boehringer Ingelheim Int Humane mangan-superoxiddismutase (hmn-sod)
DE3800973C2 (de) * 1987-03-25 1992-03-19 Degussa Ag, 6000 Frankfurt, De Oxowolfram(v)-porphyrin-komplexe wo(p)x
US5223538A (en) 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
US5227405A (en) 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US4892941A (en) 1987-04-17 1990-01-09 Dolphin David H Porphyrins
US4851403A (en) 1987-04-21 1989-07-25 Johnson Matthey, Inc. Radiation sensitizers
US5051337A (en) 1987-06-10 1991-09-24 Director-General Of Agency Of Industrial Science And Technology Optical recording material
DE3805697A1 (de) * 1988-02-24 1989-09-07 Bayer Ag Verfahren zur herstellung von p-hydroxy-benzaldehyden
US5162519A (en) 1988-03-11 1992-11-10 Efamol Holdings Plc Porphyrins and cancer treatment
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
DE3809671A1 (de) * 1988-03-18 1989-09-28 Schering Ag Porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5284647A (en) 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
US5192788A (en) * 1988-05-23 1993-03-09 Georgia State University Foundation, Inc. Porphyrin antiviral compositions
US5109016A (en) * 1988-05-23 1992-04-28 Georgia State University Foundation, Inc. Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions
US5171680A (en) 1988-06-14 1992-12-15 Chiron Corporation Superoxide dismutase analogs having novel binding properties
JPH0746212B2 (ja) 1988-12-03 1995-05-17 工業技術院長 異方性ｌｂ膜の製造法
JPH02213088A (ja) * 1989-02-13 1990-08-24 Nec Corp 有機薄膜ｅｌ素子及びその製造方法
DE69027383T2 (de) 1989-03-06 1996-11-14 Masayasu Inoue Neue superoxyd-dismutase
DK455789D0 (da) 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
US5010073A (en) * 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
EP0424033A3 (en) 1989-10-19 1991-07-31 Pola Chemical Industries Inc External skin preparation
US5236915A (en) 1990-05-31 1993-08-17 Health Research, Inc. Meso poly(4-sulfonatophenyl) porphines as MRI image enhancing agents
EP0462836A3 (en) 1990-06-20 1992-08-26 Mitsui Toatsu Chemicals, Inc. Recombinant vector plasmid capable of expressing human manganese superoxide dismutase, and process of producing this enzyme
US5417111A (en) * 1990-08-17 1995-05-23 Analog Devices, Inc. Monolithic chip containing integrated circuitry and suspended microstructure
US5217966A (en) 1990-09-13 1993-06-08 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
US5202317A (en) 1990-09-13 1993-04-13 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
AU8947791A (en) 1990-11-01 1992-05-26 Scripps Research Institute, The Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
JPH06504041A (ja) * 1990-11-14 1994-05-12 ユー・エー・ビー・リサーチ　ファウンデーション 虚血性傷害を減少させる方法と組成
US5192757A (en) * 1990-12-20 1993-03-09 Glaxo Inc. Cobalt porphyrins
ATE141502T1 (de) * 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
GB9103991D0 (en) 1991-02-26 1991-04-10 Nat Res Dev Molecular electronic devices
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
FR2676738B1 (fr) 1991-05-22 1995-05-05 Ir2M Nouveau derive organique de metal de transition a structure porphyrinique, composition therapeutique le contenant, en particulier a activite hypoglycemiante.
CA2072934C (en) * 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
JP3155552B2 (ja) 1991-07-19 2001-04-09 モンサント カンパニー 超酸化物の不均斉変化に有効な触媒としての窒素含有−大環状リガンドのマンガン錯体
US5262532A (en) 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US5212300A (en) 1991-09-12 1993-05-18 Sun Company, Inc. (R&M) Cyano- and polycyanometallo-porphyrins as catalysts for alkane oxidation
US6011146A (en) * 1991-11-15 2000-01-04 Institut Pasteur Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
US5493017A (en) 1992-08-14 1996-02-20 The Trustees Of The University Of Pennsylvania Ring-metalated porphyrins
US5371199B1 (en) 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
US5599924A (en) 1992-08-14 1997-02-04 Trustees Of The University Of Pennsylvania Electron-deficient porphyrins and processes and intermediates for preparing same
ATE201595T1 (de) 1992-09-03 2001-06-15 Univ California Metallporphyrinzusammensetzungen
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5834509A (en) * 1992-12-07 1998-11-10 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
DE4305523A1 (de) 1993-02-17 1994-08-18 Diagnostikforschung Inst Meso-Tetraphenylporphyrin-Komplexverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5428037A (en) 1993-04-09 1995-06-27 Syntex Pharmaceuticals, Ltd. Heterocyclic derivatives in the treatment of Ischaemia and related diseases
JP3273082B2 (ja) 1993-06-18 2002-04-08 三和電気工業株式会社 光コネクタ用スリ−ブホルダ
JPH0743337A (ja) * 1993-07-30 1995-02-14 Toppan Printing Co Ltd マンガンポルフィリン錯体を感応物質とする陰イオン選択性電極
US6417182B1 (en) * 1993-08-25 2002-07-09 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US5747026A (en) 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5488145A (en) 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US5608054A (en) 1993-12-29 1997-03-04 Sun Company, Inc. (R&M) Porphyrins and metal complexes thereof having haloalkyl side chains
US5405369A (en) * 1994-01-25 1995-04-11 Medical College Of Ohio Photochemical ablation of gastro-intestinal tissue for augmentation of an organ
US5604199A (en) * 1994-03-29 1997-02-18 The Nemours Foundation Method of treating fibrosis in skeletal muscle tissue
US6245758B1 (en) * 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
CZ323496A3 (en) * 1994-05-13 1997-10-15 Monsanto Co Pharmaceutical composition containing a catalyst of peroxy nitrite decomposition
US5563132A (en) * 1994-06-21 1996-10-08 Bodaness; Richard S. Two-step cancer treatment method
WO1996009053A1 (en) 1994-09-20 1996-03-28 Duke University Oxidoreductase activity of manganic porphyrins
CA2132690A1 (en) 1994-09-22 1996-03-23 Dean Willis Control and modulation of inflammatory response in humans in need of such control and modulation
US6013241A (en) * 1995-01-23 2000-01-11 Schering Aktiengesellschaft Use of porphyrin-complex or expanded porphyrin-complex compounds as an infarction localization diagnosticum
IL122451A0 (en) * 1995-06-07 1998-06-15 Univ Duke Oxidant scavengers
EP0846003A1 (en) 1995-08-17 1998-06-10 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
AU6722496A (en) * 1995-08-17 1997-03-12 Monsanto Company Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
AU700958B2 (en) 1995-08-17 1999-01-14 Monsanto Company Bioconjugates of manganese complexes and their application as catalysts
US5648523A (en) * 1995-10-26 1997-07-15 Chiang Long Y Fullerene derivatives as free-radical scavengers
US5948771A (en) * 1996-01-31 1999-09-07 The Trustees Of Columbia University In The City Of New York Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
EP0888115A1 (en) 1996-03-13 1999-01-07 Monsanto Company Iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
KR19990087784A (ko) 1996-03-13 1999-12-27 죤 에이치. 뷰센 초과산화물을 불균등화하기 위한 촉매로서 효과적인 질소함유거대고리 리간드의 망간 또는 철착물의 바이오콘쥬게이트
JPH1062350A (ja) * 1996-08-14 1998-03-06 Ebara Corp ガス反応性色素を用いたガス検知方法及びガス検知装置
US5756492A (en) * 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
WO1998033503A1 (en) 1997-02-05 1998-08-06 Board Of Regents, The University Of Texas System Porphyrin compounds as telomerase inhibitors
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
GB9716446D0 (en) 1997-08-05 1997-10-08 Agrevo Uk Ltd Fungicides
US6620961B1 (en) 1997-08-26 2003-09-16 Kumiai Chemical Industry Co., Ltd. Biarylalkylenecarbamic acid derivatives and bacteriocides for agricultural and horticultural use
JP3564962B2 (ja) * 1997-08-26 2004-09-15 松下電器産業株式会社 光記録媒体及びその光記録再生方法
ES2198767T3 (es) 1997-11-03 2004-02-01 Duke University Porfirinas sustituidas.
DE69928655T2 (de) 1998-04-24 2006-08-24 Duke University Substituierte porphyrine
CA2337756A1 (en) 1998-07-23 2000-02-03 Otto F. Schall Libraries of polyhydroxamates and their analogs
WO2000023568A2 (en) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
EP1616869B1 (en) * 1999-01-25 2012-04-04 National Jewish Health Substituted porphyrins and their therapeutic use
DE60037768T2 (de) 1999-05-27 2009-01-15 Pharmacia Corp.(N.D.Ges.D.Staates Delaware) Biomaterialien, modifiziert mit Superoxid-Dismutase Imitatoren
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
US6608050B2 (en) * 1999-07-20 2003-08-19 Pharmacia & Upjohn Company Lyophilizate of lipid complex of water insoluble porphyrins
US6372727B1 (en) * 1999-10-13 2002-04-16 Uab Research Foundation Metalloporphyrin treatment of neurologic disease
EP1148057A4 (en) * 1999-11-30 2002-05-29 Photochemical Co Ltd PORPHYRIN COMPLEX SUPPORTING A NITROIMIDAZOLE
JP3383839B2 (ja) * 2000-03-13 2003-03-10 奈良先端科学技術大学院大学長 新規なメルカプト置換イミダゾリルポルフィリン金属錯体単量体及びこれを繰り返し単位として有する重合体並びにこれらの製造方法
US6624187B1 (en) * 2000-06-12 2003-09-23 Health Research, Inc. Long wave length absorbing bacteriochlorin alkyl ether analogs
CA2412623A1 (en) 2000-06-14 2001-12-20 Brian J. Day Tetrapyrroles
US6403788B1 (en) 2000-07-11 2002-06-11 Eukarion, Inc. Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
US6573258B2 (en) * 2000-09-27 2003-06-03 Frontier Scientific, Inc. Photodynamic porphyrin antimicrobial agents
AU2002248366B2 (en) * 2001-01-19 2006-10-26 Aeolus Sciences, Inc. Cancer therapy
WO2002078670A1 (en) 2001-03-02 2002-10-10 Neuron Therapeutics, Inc. Neuroprotectants formulations and methods
US6827926B2 (en) 2001-05-31 2004-12-07 Miravant Pharmaceuticals, Inc. Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
US6566517B2 (en) * 2001-06-06 2003-05-20 Brookhaven Science Associates, Llc Metalloporphyrins and their uses as imageable tumor-targeting agents for radiation therapy
DE10240343A1 (de) 2002-08-27 2004-03-11 Schering Ag Peroxynitrit-Umlagerungskatalysatoren
WO2005077269A1 (en) 2004-02-09 2005-08-25 Duke University Substituted porphyrins
JP2008538586A (ja) 2005-04-21 2008-10-30 グレン エー． ゴールドスタイン， 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
US20120289492A1 (en) 2009-09-02 2012-11-15 The Regents Of The University Of Colorado, A Body Corporate Methods of treating mitochondrial disorders using metalloporphyrins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885114A (en) * 1987-04-22 1989-12-05 Barnes Engineering Co. Metallized tetra((meso)-5-methyl-2-thiophene)porphines, platinum (5-bromo octaethylporphine) and optical filters containing same
US5236914A (en) * 1988-06-02 1993-08-17 Centre National De La Recherche Scientifique (Cnrs) Derivatives of metalloporphyrins and application thereof for therapeutic purposes and in preparing hybrid molecules

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6583132B1 (en) 1993-10-15 2003-06-24 Duke University Oxidant scavengers
EP1442747A1 (en) * 1993-10-15 2004-08-04 Duke University Superoxide dismutase and mimetics thereof
US6479477B1 (en) 1998-04-24 2002-11-12 Duke University Substituted porphyrins
US6544975B1 (en) 1999-01-25 2003-04-08 National Jewish Medical And Research Center Substituted porphyrins
US7820644B2 (en) 1999-01-25 2010-10-26 Aelous Pharmaceuticals, Inc. Substituted porphyrins
US8546562B2 (en) 1999-01-25 2013-10-01 James D. Crapo Substituted porphyrins
US7189707B2 (en) 1999-01-25 2007-03-13 National Jewish Medical Research Center Substituted porphyrins
US8217026B2 (en) 1999-01-25 2012-07-10 Aeolus Sciences, Inc. Substituted porphyrins
US9289434B2 (en) 1999-01-25 2016-03-22 Aeolus Sciences, Inc. Substituted porphyrins
US8946202B2 (en) 1999-01-25 2015-02-03 Aeolus Sciences, Inc. Substituted porphyrins
US8470808B2 (en) 1999-01-25 2013-06-25 Jon D. Piganelli Oxidant scavengers for treatment of type I diabetes or type II diabetes
WO2001072327A3 (fr) * 2000-03-28 2002-03-28 Univ Paris Descartes Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
FR2806911A1 (fr) * 2000-03-28 2001-10-05 Univ Rene Descartes Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
JP2009242421A (ja) * 2001-01-19 2009-10-22 National Jewish Health 癌治療
US8765729B2 (en) 2001-01-19 2014-07-01 Aeolus Sciences, Inc. Cancer therapy
WO2002060383A3 (en) * 2001-01-19 2003-12-11 Nat Jewish Med & Res Center Cancer therapy
AU2002253619B2 (en) * 2001-04-27 2007-05-17 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same active ingredients
EP1439842A4 (en) * 2001-06-01 2009-09-02 Nat Jewish Med & Res Center OXIDANT CAPTAIN FOR THE TREATMENT OF DIABETES OR FOR THE USE IN THE TRANSPLANTATION OR INDUCTION OF IMMUNOTOLERANE
US7432369B2 (en) 2004-03-29 2008-10-07 Inotek Pharmaceuticals Corporation Pyridyl-substituted porphyrin compounds and methods of use thereof
WO2008070579A3 (en) * 2006-12-01 2009-03-19 Univ Loma Linda Med Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration
KR101646066B1 (ko) * 2008-05-23 2016-08-05 내셔날 쥬이쉬 헬스 알킬화 종으로의 노출과 관련된 상해를 치료하는 방법
EP2732817A1 (en) * 2008-05-23 2014-05-21 National Jewish Health A compound for use in treating injury associated with exposure to phosgene or chlorine gas
EP2300003A4 (en) * 2008-05-23 2012-04-04 Nat Jewish Health METHOD FOR TREATING INJURIES DUE TO SUSPENSION AGAINST AN ALKYLATIVE SPECIES
KR20110017398A (ko) * 2008-05-23 2011-02-21 내셔날 쥬이쉬 헬스 알킬화 종으로의 노출과 관련된 상해를 치료하는 방법
US11382895B2 (en) 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
AU2009280042B2 (en) * 2008-05-23 2015-06-04 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
EP2435387A4 (en) * 2009-05-26 2013-03-20 Univ Duke PROCESS FOR PROVIDING NERVE PROTECTION THROUGH THE USE OF PORPHYRINES
EP2625180A4 (en) * 2010-10-06 2014-05-14 Aeolus Sciences Inc PORPHYRINE TREATMENT OF NEURODEEGENERATIVE DISEASES
US20130225545A1 (en) * 2010-10-06 2013-08-29 Aeolus Sciences, Inc. Porphyrin treatment of neurodegenerative diseases
US10124011B2 (en) 2013-09-03 2018-11-13 Biomimetix Jv, Llc Methods of treating erectile dysfunction
US9999627B2 (en) 2013-09-03 2018-06-19 BioMimetix, JV, LLC Methods of treating erectile dysfunction
WO2015034777A1 (en) * 2013-09-03 2015-03-12 Biomimetix J.V., Llc Methods of treating biofilms
WO2015034778A1 (en) * 2013-09-03 2015-03-12 Biomimetix J.V., Llc Methods of treating erectile dysfunction
US10064871B2 (en) 2014-01-22 2018-09-04 Biomimetix Jv, Llc Methods of treating skin disorders
US10080759B2 (en) 2014-01-22 2018-09-25 Duke University Methods of treating pruritus
US11065259B2 (en) 2014-01-22 2021-07-20 Duke University Methods of treating pruritus
WO2016077857A1 (de) * 2014-11-20 2016-05-26 Wenatex Forschung - Entwicklung - Produktion Gmbh Antimikrobielles mittel zum biociden ausrüsten von polymeren
WO2020250207A1 (en) * 2019-06-14 2020-12-17 Universidade De Coimbra Small cationic ortho-5,15-di-heteroaryl-porphyrins derivatives and their applications in photoinactivation of microorganisms
US12410178B2 (en) 2019-06-14 2025-09-09 Universidade De Coimbra Small cationic ortho-5,15-di-heteroaryl-porphyrin derivatives and their applications in photoinactivation of microorganisms

Also Published As

Publication number Publication date
EP1616869A1 (en) 2006-01-18
US7189707B2 (en) 2007-03-13
ZA200106107B (en) 2002-12-24
US8946202B2 (en) 2015-02-03
US20070197496A1 (en) 2007-08-23
US7820644B2 (en) 2010-10-26
BR0007720B1 (pt) 2014-04-08
BR0007720A (pt) 2001-10-30
US8546562B2 (en) 2013-10-01
US20120214780A1 (en) 2012-08-23
WO2000043395A8 (en) 2000-08-31
EP1155019A1 (en) 2001-11-21
US9289434B2 (en) 2016-03-22
ATE552260T1 (de) 2012-04-15
US8217026B2 (en) 2012-07-10
NZ513164A (en) 2006-03-31
US20150231150A1 (en) 2015-08-20
EP2295435A1 (en) 2011-03-16
DK1155019T3 (da) 2006-04-18
KR20010108130A (ko) 2001-12-07
ES2254142T3 (es) 2006-06-16
US20110065679A1 (en) 2011-03-17
DE60024588D1 (de) 2006-01-12
US20040023941A1 (en) 2004-02-05
CA2359116C (en) 2009-03-17
DE60024588T2 (de) 2006-08-17
CA2359116A1 (en) 2000-07-27
KR100753184B1 (ko) 2007-08-30
HK1047744A1 (en) 2003-03-07
IL183953A (en) 2010-12-30
MXPA01007451A (es) 2004-03-10
CN1355802A (zh) 2002-06-26
EP1155019A4 (en) 2002-07-03
US20140011794A1 (en) 2014-01-09
IL183953A0 (en) 2007-10-31
EP1155019B1 (en) 2005-12-07
AU779283C (en) 2000-08-07
CN1156478C (zh) 2004-07-07
EP1616869B1 (en) 2012-04-04
DK1616869T3 (da) 2012-05-07
US6544975B1 (en) 2003-04-08
HK1083626A1 (en) 2006-07-07
ATE312103T1 (de) 2005-12-15
ES2385486T3 (es) 2012-07-25
JP2002535332A (ja) 2002-10-22
AU2740700A (en) 2000-08-07
JP4501128B2 (ja) 2010-07-14
IL144503A (en) 2007-10-31
AU779283B2 (en) 2005-01-13
IL144503A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU779283C (en) Substituted porphyrins
AU771259B2 (en) Substituted porphyrins
EP1045851B1 (en) Substituted porphyrins
HK1083626B (en) Substituted porphyrins and their therapeutic use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00805458.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 30/2000 UNDER (51) REPLACE THE EXISTING SYMBOLS BY "C07D487/22, C09B 47/00, A61K 51/02"

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2359116

Country of ref document: CA

Ref document number: 2359116

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 144503

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2000 594811

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007451

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017009367

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 513164

Country of ref document: NZ

Ref document number: 27407/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000905776

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000905776

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017009367

Country of ref document: KR

AK Designated states

Kind code of ref document: B8

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B8

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWG Wipo information: grant in national office

Ref document number: 27407/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000905776

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 183953

Country of ref document: IL